Brokerages Set Endo International plc (NASDAQ:ENDP) Price Target at $7.36

Endo International plc (NASDAQ:ENDP) (TSE:ENL) has been given an average rating of “Hold” by the nine ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.36.

ENDP has been the subject of several research analyst reports. Piper Sandler downgraded Endo International from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $10.00 to $3.00 in a research note on Tuesday, August 31st. Royal Bank of Canada reduced their target price on Endo International from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Monday, August 9th.

Shares of NASDAQ:ENDP opened at $4.12 on Monday. Endo International has a 12-month low of $1.94 and a 12-month high of $10.89. The company has a market capitalization of $962.02 million, a PE ratio of 14.71 and a beta of 1.37. The business has a 50 day moving average of $3.16 and a two-hundred day moving average of $4.63.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, August 5th. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.17. The business had revenue of $713.83 million during the quarter, compared to the consensus estimate of $657.27 million. Endo International had a negative return on equity of 94.51% and a net margin of 2.46%. During the same period in the prior year, the company posted $0.65 EPS. On average, equities research analysts anticipate that Endo International will post 2.29 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in shares of Endo International by 63.0% in the second quarter. Russell Investments Group Ltd. now owns 418,260 shares of the company’s stock valued at $1,957,000 after purchasing an additional 161,675 shares during the period. Geode Capital Management LLC raised its holdings in Endo International by 15.5% in the first quarter. Geode Capital Management LLC now owns 4,105,987 shares of the company’s stock valued at $30,425,000 after acquiring an additional 549,953 shares in the last quarter. Tudor Investment Corp Et Al acquired a new stake in Endo International in the first quarter valued at approximately $941,000. LSV Asset Management raised its holdings in Endo International by 1,928.1% in the second quarter. LSV Asset Management now owns 452,259 shares of the company’s stock valued at $2,116,000 after acquiring an additional 429,959 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp raised its holdings in Endo International by 19.0% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 245,380 shares of the company’s stock valued at $1,762,000 after acquiring an additional 39,180 shares in the last quarter. 79.73% of the stock is owned by institutional investors and hedge funds.

About Endo International

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.